OptimizeRx (OPRX)
(Real Time Quote from BATS)
$8.48 USD
-0.35 (-3.96%)
Updated Aug 7, 2024 01:56 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OPRX 8.48 -0.35(-3.96%)
Will OPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPRX
NuScale Power (SMR) to Post Q2 Earnings: What's in Store?
DigitalOcean (DOCN) to Post Q2 Earnings: What's in Store?
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy?
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
Other News for OPRX
Lake Street Remains a Buy on OptimizeRx (OPRX)
OptimizeRx resumed with a Buy at B. Riley
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
OptimizeRx delivers AI-guided privacy-compliant platform